Thermo Fisher raises guidance on 'fabulous' biopharma services growth

By Dan Stanton contact

- Last updated on GMT

Thermo Fisher is at “the end of the first quarter with three quarters to go,” CEO Marc Casper said describing potential growth in biopharma services
Thermo Fisher is at “the end of the first quarter with three quarters to go,” CEO Marc Casper said describing potential growth in biopharma services

Related tags: Thermo fisher, Life

The biopharma services market keeps expanding and “growth prospects look fabulous,” says Thermo Fisher, reporting better than expected sales across its Life Sciences business for the second quarter 2014.

For Q2 2014, Thermo Fisher’s Life Sciences Solutions business revenues shot up 500% year-on-year to $1.1bn (€820m) due primarily to the incorporation of Life Technologies, which the firm acquired for $13.6bn​ in February this year.

The integration process is going well with “synergies tracking ahead of plan,”​ the company said.

The Life Sciences Solutions unit now accounts for just over 25% of the company’s total revenue and growing demand for biopharma services has led to a slight increase in Thermo Fisher’s growth outlook for the full-year, CEO Marc Casper said in a conference call.

“Biopharma service is a great business,”​ he told investors (transcript here​). “It’s been doing great for a long period of time, and continues to do well,” ​with pharma firms continuing to outsource to Thermo Fisher as “the low-cost, high-quality provider.”

When asked about the penetration rate of the biopharma business, Casper said it was hard to give a figure as both Thermo Fisher’s customer base and its service offerings are expanding.

“We continue to add service lines but we’ve had customers say you do this so well, we like you to do syringe work with us, where we might have been doing other types of outsourcing works,”​ he said. “We just did our strategic plan review, which is a five year outlook for that business, and growth prospects look fabulous.”

When pushed as to how much the biopharma business could grow, Casper described the firm as at “the end of the first quarter with three quarters to go”​ in a nod to the upcoming American Football season.

The quarter also saw the company commence expansion at its Centres of Excellence in Vilnius, Lithuania and Bremen, Germany, adding manufacturing capacity to support growth of molecular biology products for life sciences and diagnostics.

Related news

Show more

Related products

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Partner with Experts in Precision Medicine

Partner with Experts in Precision Medicine

CellCarta | 17-Jan-2022 | Product Brochure

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...

Related suppliers